An Open-label, Randomized, Single-dose, 4-period, 4-sequence Crossover Relative Bioavailability Study Comparing Sotagliflozin Prototypes Tablets With Reference Tablet in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Sanofi
- 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Oct 2017 New trial record
- 18 Oct 2017 Status changed from not yet recruiting to recruiting.